Drug Target Review Q&A with Cellarity

Section HeadingSection Content

Cellarity’s CEO Fabrice Chouraqui spoke with Drug Target Review about the advantages of targeting the whole cell rather than a single molecular target in drug discovery. This approach allows us to unravel the complexity of disease biology and discover new drugs, even when there is no known target.

Read the full Q&A here.

Up Next

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases